price following cr, page-3

I'm not sure how these stocks rerate by themselves without news. Would love it if it did just one day rerate due to one of my posts haha.

Something to throw into the mix on that score is that, courtesy of a rhuematology researcher I talked to yesterday, the second generation of anti-TNF drugs due out soon have been showing disappointing results in their phase 3 trials. They work, but not that well. Public knowledege, but perhaps not widely known. That's not good news for the rest of the world, except for companies with interesting molecules like CPN10.

re the current price. If the holders of current stock sold 5% to take advantatge of the placement, we'd have 20m shares odd worth of offers. We've probably had 3 or 4 m total volume do you reckon so far. Due to the high spec nature of the stock i'm sure there is rebalancing going on, as some people have reached their limit on what they can spend on itsy bitsy biotechs.